| Bioactivity | Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X[1]. Tecarfarin sodium has the antithrombotic activity[2]. |
| Target | VKOR |
| Name | Tecarfarin sodium |
| CAS | 1004551-83-0 |
| Formula | C21H13F6NaO5 |
| Molar Mass | 482.31 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hobl EL, et al. Tecarfarin: A Novel Vitamin K Antagonist. Thromb Haemost. 2017 Nov;117(11):2009-2011. [2]. Bowersox SS, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res. 2010 Nov;126(5):e383-8. |
Tecarfarin sodium
CAS: 1004551-83-0 F: C21H13F6NaO5 W: 482.31
Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagoni
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.